
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

MEDICINOVA INC

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

(CUSIP Number)

**3D Investment Partners Pte. Lt
1 Temasek Avenue, #20-02A Millenia Tower
Singapore, U0, 039192
65 6819 0000**

**Greenberg Traurig, LLP
One Vanderbilt Avenue,
New York, NY, 10017
(212) 801 9200**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/25/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	3D Investment Partners Pte. Ltd.
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	SINGAPORE
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	
Beneficially	8
Owned by	4,862,047.00
Each	Sole Dispositive Power
Reporting	9
Person	0.00
With:	Shared Dispositive Power
	10
	4,862,047.00
	Aggregate amount beneficially owned by each reporting person
11	4,862,047.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	9.9 %
	Type of Reporting Person (See Instructions)
14	IA, OO

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	3D Opportunity Master Fund
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

	☐	Citizenship or place of organization
6		CAYMAN ISLANDS
		Sole Voting Power
	7	
Number of		0.00
Shares		Shared Voting Power
Beneficially	8	
Owned by		4,862,047.00
Each		Sole Dispositive Power
Reporting	9	
Person		0.00
With:		Shared Dispositive Power
	10	
		4,862,047.00
		Aggregate amount beneficially owned by each reporting person
11		4,862,047.00
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12		
	☐	Percent of class represented by amount in Row (11)
13		9.9 %
		Type of Reporting Person (See Instructions)
14		OO

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.001 per share

Name of Issuer:

(b)

MEDICINOVA INC

Address of Issuer's Principal Executive Offices:

(c)

4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CALIFORNIA , 92037.

Item 1 This Amendment No. 2 ("Amendment No. 2") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") originally filed by the Reporting Persons on January 21, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed by the Reporting Persons on July 12, 2022 ("Amendment No. 1", and together with the Original Schedule 13D and this Amendment No. 2, "Schedule 13D"), relating to the Shares of the Issuer. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Schedule 13D. Unless otherwise indicated, each capitalized term used but not defined in this Amendment No. 2 shall have the meaning assigned to such term in the Schedule 13D.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Except as set forth in this Schedule 13D, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. As part of its periodic evaluation of their investment in the Issuer, the Reporting Persons intend to review their investment in the Issuer. The Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. In reaching any decision as to their course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that they would take into consideration a variety of factors, including, but not limited to, the following: the Issuer's financial position and strategic direction; actions taken by the Issuer's Board of Directors; the Issuer's business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Reporting Persons; changes in law and government regulations; general economic and industry conditions; tax considerations; and money and stock market conditions, including the market price of the securities of the Issuer. As of 2024, the Reporting Persons' Observer Appointment Right under the Shareholder Rights Agreement lapsed under

the terms of the agreement, and the Reporting Persons no longer have an Observer appointed to attend meetings of the board of directors of the Issuer.

Item 5. Interest in Securities of the Issuer

Item 5(a) of Schedule 13D is hereby amended and restated as follows: The responses of each Reporting Person to Rows (11) and (13) of the cover pages of this Amendment No. 2 are hereby incorporated by reference into this Item 5(a). As of September 25, 2026, the Reporting Persons may be deemed to be the beneficial owners of up to 4,862,047 Shares of the Issuer, which constitutes beneficial ownership of approximately 9.9% of the issued and outstanding Shares of the Issuer (based on 49,221,246 Shares outstanding as of August 11, 2026, as reported in the Issuer's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026).

(a) Item 5(b) of Schedule 13D is hereby amended and restated as follows: The responses of each Reporting Person to Rows (7) through (10) of the cover pages of this Amendment No. 2 are hereby incorporated by reference into this Item 5(b). 3DIP and 3DOMF have shared power to vote up to 4,862,047 Shares of the Issuer and have shared investment power with respect to such Shares, and thus, each Reporting Person may be deemed to be the beneficial owner of 4,862,047 Shares of the Issuer. As described in Item 2 of Schedule 13D, 3DOMF has delegated all voting and investment power over the Shares to 3DIP as its investment manager.

(b) Item 5(c) of Schedule 13D is hereby amended and supplemented as follows: Pursuant to an accelerated share disposal ("ADS") transaction entered into with a third-party financial institution, on September 25, 2026, the Reporting Persons sold in a private sale to said third-party financial institution 640,000 Shares of the Issuer for a price of JPY425 (approximately US\$ 2.7) per share. The Reporting Persons do not have the power to vote or direct the voting or to dispose of or direct the disposition of the Shares sold as part of the ADS transaction and therefore ceased to have beneficial ownership over such Shares.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and supplemented as follows: The Reporting Persons have entered into certain cash-settled total return swap agreements (the "Cash-Settled TRS") with an unaffiliated third-party financial institution as counterparty, which provide the Reporting Persons with economic exposure to an aggregate of 456,637 notional shares, representing approximately 0.9% of the outstanding Shares of the Issuer. The Cash-Settled TRS provide the Reporting Persons with economic results that are comparable to the economic results of ownership, but do not provide the Reporting Persons with the power to vote or direct the voting or to dispose of or direct the disposition of the Shares that are the subject of the Cash-Settled TRS; therefore, the Reporting Persons disclaim any beneficial ownership of any shares that may be referenced in the Cash-Settled TRS. The Reporting Persons do not have the right to convert the Cash-Settled TRS into Shares of the Issuer at any time.

Item 7. Material to be Filed as Exhibits.

Exhibit 1 Joint Filing Agreement, dated September 29, 2026, by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

3D Investment Partners Pte. Ltd.

Signature: /s/ Sai Fai Yip

Name/Title: Sai Fai Yip/Director

Date: 09/29/2026

3D Opportunity Master Fund

Signature: /s/ Sai Fai Yip

Name/Title: Sai Fai Yip/Director

Date: 09/29/2026

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value \$0.001 per share, of MediciNova, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Agreement.

Dated: September 29, 2026

3D Investment Partners Pte. Ltd.

/s/ Sai Fai Yip

Name: Sai Fai Yip

Title: Director

3D Opportunity Master Fund

/s/ Sai Fai Yip

Name: Sai Fai Yip

Title: Director